Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FIP1L1::PDGFRA status confers therapeutic sensitivity to Imatinib in patients with Chronic Eosinophilic Leukemia, NOS.
This statement is based on a regulatory approval from the Health Canada:
GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.